About us Services Why Choose CROMA The Greek Market Contact us Home

The Greek healthcare environment - Overview

The pharmaceutical industry in Greece is operating in a complex, fast changing, unpredictable environment and is exposed to regulatory and market pressures. It is of utmost importance to understand the environment and build credibility in order to achieve early Market Access.
REGULATORY BODIES
EOF - National Organization of Pharmaceuticals is the competent Authorities for the:

MINISTRY OF HEALTH

THE SOCIAL INSURANCE SYSTEM (EOPYY)

In the context of the challenging economic environment, one of the government’s measures to increase efficiency and contain health expenditure was the establishment of a Unified Healthcare Fund (EOPYY).
The National Organization for Healthcare Provision (EOPYY) constitutes the healthcare insurer and a main provider of PHC in Greece.
EOPYY is a public corporate body established under Greek Law 3918/2011 and it is supervised by the Ministry of Health (MoH).
The organization started its operations on 1st January 2012. EOPYY’s primary mission is the provision of health services to active members, pensioners and their family dependents registered to the merging healthcare funds. EOPYY unified the majority of healthcare funds, amongst them being the Private Employees’ Fund (IKA), the Public Employees’ Fund (OPAD), the Farmers’ Fund (OGA) and the self-employed/Entrepreneurs’ Fund (OAEE). As a result, EOPYY covers over the 98% of the insured population (close to 11 million).

 

GREEK HEALTH ENVIRONMENT - FACTS AND FIGURES (data from 2013)

Net public pharmaceutical expenditure is the final amount Social Security Funds have to spend to cover population needs, after deduction of discounts, rebates and clawback. From 2009 and onwards, pharmaceutical expenditure followed a downward trend, resulting in an overall decrease of 53.6% until 2013, reaching the target of €2.37 billion. This decline was the result of the fiscal adjustment program which included changes in the pricing system, increases in returns - rebates - to social security funds, reduction of regulated margins in the wholesale and retail distribution of drugs, reduction in VAT on medicines and more.

THE SUPPLY CHAIN OF PHARMACEUTICALS